Get started
Author

Andrés McAllister

Observed names: A McAllister, A. Mc Allister, A. McAllister, Andres McAllister, Andrés McAllister, Andrès McAllister
Institution: BioInvent (Sweden)
ORCID: 0009-0006-5510-444X
Observed ORCID: 0009-0006-5510-444X
OpenAlex ID: A5000250788
Role of macrophages during Theiler's virus infection
1997 · C P Rossi, M Delcroix, et al. · Journal of Virology · 128
Theiler’s Virus Infection of Perforin-Deficient Mice
1998 · Claudia Pena Rossi, Andrés McAllister, et al. · Journal of Virology · 84
PDF
Genetic mapping of the ability of Theiler's virus to persist and demyelinate
1990 · A McAllister, F Tangy, et al. · Journal of Virology · 69
Recombinant Yellow Fever Viruses Are Effective Therapeutic Vaccines for Treatment of Murine Experimental Solid Tumors and Pulmonary Metastases
2000 · Andrés McAllister, Alejandra E. Arbetman, et al. · Journal of Virology · 67
PDF
A single amino acid change determines persistence of a chimeric Theiler's virus
1994 · N Jarousse, R A Grant, et al. · Journal of Virology · 56
Theiler's virus infection induces a specific cytotoxic T lymphocyte response
1991 · Claudia Pen̄a Rossi, Andrés McAllister, et al. · Cellular Immunology · 53
Molecular cloning of the complete genome of Theiler's virus, strain DA, and production of infectious transcripts
1989 · Andrés McAllister, Frédéric Tangy, et al. · Microbial Pathogenesis · 43
Molecular cloning of the complete genome of strain GDVII of Theiler's virus and production of infectious transcripts
1989 · F Tangy, A McAllister, et al. · Journal of Virology · 37
Determinants of persistence and demyelination of the DA strain of Theiler's virus are found only in the VP1 gene
1991 · F Tangy, A McAllister, et al. · Journal of Virology · 36
PDF
Chimeric Theiler's virus with altered tropism for the central nervous system
1994 · N Jarousse, L Fiette, et al. · Journal of Virology · 19
Role of VP2 amino acid 141 in tropism of Theiler's virus within the central nervous system
1996 · N Jarousse, C Martinat, et al. · Journal of Virology · 17
Genetic determinants of the demyelinating disease caused by Theiler's virus
1991 · Michel Brahic, Jean-François Bureau, et al. · Microbial Pathogenesis · 15
The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34+ Stem/Progenitor Cells
2017 · Maximilien Murone, Ramin Radpour, et al. · Molecular Cancer Therapeutics · 14
725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy
2020 · Linda Mårtensson, Mathilda Kovacek, et al. · Journal for ImmunoTherapy of Cancer · 9
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases
2016 · Maximilien Murone, Anne Vaslin Chessex, et al. · Molecular Cancer Therapeutics · 8
19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.
2024 · Kristoffer Staal Rohrberg, Zsuzsanna Papai, et al. · Journal of Clinical Oncology · 7
PDF
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcγriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab
2021 · Ingrid Karlsson, Susanne Gertsson, et al. · Blood · 4
17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab
2020 · Mats Jerkeman, Andres McAllister, et al. · Blood · 4
BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter, showing promising efficacy in T cell lymphoma patients
2025 · Stefan Barta, Christiane Querfeld, et al. · Blood · 3
PDF
A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
2025 · Javier Cortés, Araceli Priego, et al. · Clinical Cancer Research · 3
PDF
757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab
2023 · Kristoffer Staahl Rohrberg, Zsuzsanna Papai, et al. · Journal for ImmunoTherapy of Cancer · 3
PDF
Abstract 4156: BI-1808 - a first in class ligand-blocking αTNFR2 antibody for cancer immunotherapy
2022 · Linda Mårtensson, Kirsty Cleary, et al. · Cancer Research · 3
1024P Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
2024 · S. Champiat, C. Lebbe, et al. · Annals of Oncology · 2
1073TiP A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors
2024 · T.C. Hernandez Guerrero, B. Doger de Spéville, et al. · Annals of Oncology · 2
PDF
1368 Preclinical development of an agonistic anti-TNFR2 antibody (BI-1910) for cancer immunotherapy
2023 · Linda Martensson, Petra Holmkvist, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Works count: 81
Citation count: 692
H-index: 13
I10-index: 13
Year
Topic
Type